Jeremy Bender
Vorstandsvorsitzender bei DAY ONE BIOPHARMACEUTICALS, INC.
Vermögen: 22 Mio $ am 30.04.2024
Aktive Positionen von Jeremy Bender
Unternehmen | Position | Beginn | Ende |
---|---|---|---|
MEREO BIOPHARMA GROUP PLC | Direktor/Vorstandsmitglied | 01.10.2020 | - |
DAY ONE BIOPHARMACEUTICALS, INC. | Direktor/Vorstandsmitglied | 01.09.2020 | - |
Vorstandsvorsitzender | 01.09.2020 | - | |
Präsident | 01.09.2020 | - | |
FUSN PHAR | Direktor/Vorstandsmitglied | 16.10.2023 | - |
DOT Therapeutics-2, Inc.
DOT Therapeutics-2, Inc. Pharmaceuticals: MajorHealth Technology DOT Therapeutics-2, Inc. develops new therapies that change the outcome for people of all ages living with cancer. The company was founded by Julie Grant and Samuel Blackman and is headquartered in South San Francisco, CA. | Vorstandsvorsitzender | - | - |
Karriereverlauf von Jeremy Bender
Ehemalige bekannte Positionen von Jeremy Bender
Unternehmen | Position | Beginn | Ende |
---|---|---|---|
GILEAD SCIENCES, INC. | Corporate Officer/Principal | 01.03.2018 | 01.09.2020 |
Tizona Therapeutics, Inc.
Tizona Therapeutics, Inc. BiotechnologyHealth Technology Tizona Therapeutics, Inc. is an immunology company harnessing the power of the immune system to develop treatments for cancer and autoimmune diseases. Its products include anti-ccr4 antibody for the treatment of cancer, il-35 antagonists for the treatment of cancer, and il-35 agonists for the treatment of autoimmune diseases. The company was founded by Charles G. Drake, Vijay K. Kuchroo, Drew M. Pardoll, Dario Vignali, Wayne A. Marasco and Jedd D. Wolchok and is headquartered in South San Francisco, CA. | Geschäftsführer | 01.07.2015 | 01.03.2018 |
SUTRO BIOPHARMA, INC. | Corporate Officer/Principal | 24.10.2012 | 01.07.2015 |
Allos Therapeutics, Inc.
Allos Therapeutics, Inc. Pharmaceuticals: MajorHealth Technology Allos Therapeutics, Inc. is a biopharmaceutical company committed to the development and commercialization of innovative anti-cancer therapeutics. It focuses on the development and commercialization FOLOTYN a pralatrexate injection. FOLOTYN is a folate analogue metabolic inhibitor designed to accumulate preferentially in cancer cells. It targets the inhibition of dihydrofolate reductase, or DHFR, an enzyme critical in the folate pathway, thereby interfering with DNA and RNA synthesis and triggering cancer cell death. Allos Therapeutics is also developing FOLOTYN in other hematologic malignancies and solid tumors. The company was founded on September 1, 1992 and is headquartered in Westminster, CO. | Corporate Officer/Principal | 01.01.2006 | 01.09.2012 |
The Boston Consulting Group, Inc.
The Boston Consulting Group, Inc. Miscellaneous Commercial ServicesCommercial Services The Boston Consulting Group, Inc. engages in the provision of management consulting services. It specializes in automotive and mobility; biopharmaceuticals; consumer products; education; oil and gas; power and utilities; engineered products and infrastructure; financial institutions; and health care payers, providers, and services. It offers big data and advanced analytics; change management; client learning and enablement; and corporate development and financial services. The company was founded by Bruce Doolin Henderson in 1963 and is headquartered in Boston, MA. | Corporate Officer/Principal | - | - |
Ausbildung von Jeremy Bender
The University of Colorado | Doctorate Degree |
Stanford University | Undergraduate Degree |
MIT Sloan School of Management | Masters Business Admin |
Statistik
International
Vereinigte Staaten | 11 |
Vereinigtes Königreich | 2 |
Kanada | 2 |
Operativ
Corporate Officer/Principal | 4 |
Director/Board Member | 3 |
Chief Executive Officer | 2 |
Sektoral
Health Technology | 9 |
Consumer Services | 4 |
Commercial Services | 2 |
Besetzte Positionen
Aktive
Inaktive
Börsennotierte Unternehmen
Private Unternehmen
Unternehmensverbindungen
Börsennotierte Unternehmen | 5 |
---|---|
SUTRO BIOPHARMA, INC. | Health Technology |
MEREO BIOPHARMA GROUP PLC | Health Technology |
DAY ONE BIOPHARMACEUTICALS, INC. | Health Technology |
GILEAD SCIENCES, INC. | Health Technology |
FUSN PHAR | Health Technology |
Private Unternehmen | 4 |
---|---|
Allos Therapeutics, Inc.
Allos Therapeutics, Inc. Pharmaceuticals: MajorHealth Technology Allos Therapeutics, Inc. is a biopharmaceutical company committed to the development and commercialization of innovative anti-cancer therapeutics. It focuses on the development and commercialization FOLOTYN a pralatrexate injection. FOLOTYN is a folate analogue metabolic inhibitor designed to accumulate preferentially in cancer cells. It targets the inhibition of dihydrofolate reductase, or DHFR, an enzyme critical in the folate pathway, thereby interfering with DNA and RNA synthesis and triggering cancer cell death. Allos Therapeutics is also developing FOLOTYN in other hematologic malignancies and solid tumors. The company was founded on September 1, 1992 and is headquartered in Westminster, CO. | Health Technology |
The Boston Consulting Group, Inc.
The Boston Consulting Group, Inc. Miscellaneous Commercial ServicesCommercial Services The Boston Consulting Group, Inc. engages in the provision of management consulting services. It specializes in automotive and mobility; biopharmaceuticals; consumer products; education; oil and gas; power and utilities; engineered products and infrastructure; financial institutions; and health care payers, providers, and services. It offers big data and advanced analytics; change management; client learning and enablement; and corporate development and financial services. The company was founded by Bruce Doolin Henderson in 1963 and is headquartered in Boston, MA. | Commercial Services |
DOT Therapeutics-2, Inc.
DOT Therapeutics-2, Inc. Pharmaceuticals: MajorHealth Technology DOT Therapeutics-2, Inc. develops new therapies that change the outcome for people of all ages living with cancer. The company was founded by Julie Grant and Samuel Blackman and is headquartered in South San Francisco, CA. | Health Technology |
Tizona Therapeutics, Inc.
Tizona Therapeutics, Inc. BiotechnologyHealth Technology Tizona Therapeutics, Inc. is an immunology company harnessing the power of the immune system to develop treatments for cancer and autoimmune diseases. Its products include anti-ccr4 antibody for the treatment of cancer, il-35 antagonists for the treatment of cancer, and il-35 agonists for the treatment of autoimmune diseases. The company was founded by Charles G. Drake, Vijay K. Kuchroo, Drew M. Pardoll, Dario Vignali, Wayne A. Marasco and Jedd D. Wolchok and is headquartered in South San Francisco, CA. | Health Technology |
- Börse
- Insiders
- Jeremy Bender
- Erfahrung